[Etravirine in clinical practice: Experience in 151 non-naïve patients].
There are limited data on etravirine (ETV) use in routine clinical practice. The reasons, efficacy and tolerability of its use are retrospectively reviewed. Overall, 151patients started a regimen containing ETV. The main reasons for prescription were toxicity and virological failure. After a median follow-up of 16months 76.2% of the patients had an undetectable viral load. Patients with detectable HIV-RNA at baseline had a greater risk of failure (31.7% vs 18%; P=.05). ETV is safe, effective and durable.